In a recent NOTW, I shared what I believed to be the three reasons behind the weakness (in relevance order): The narrative around oral GLP-1s Schotts weak FY 2026 guidance (shared early in December) Stevanatos low float (80% or so remains in the hands of the Stevanato family) #3 is what it is and we cant do much about it
If that describes you, this is worth flagging explicitly to your doctor before any treatment decision
This slowdown keeps you feeling full for longer, which further reduces your food intake
Although no one has quite discovered an answer to the aging process, the quest for the fountain of youth continues to be pursued by many
Studies indicate that adequate levels of B12 may reduce the risk of neurodegenerative diseases like Alzheimers
The real goal is to keep you feeling well, energetic, and mentally sharp, without the dips that can happen between doses